Thermo Fisher Scientific Inc.
TMO
$691.33
-1.27%
Thermo Fisher Scientific is the world's largest pure-play life sciences tools and diagnostics company, selling analytical instruments, laboratory equipment, specialty diagnostics consumables, and life science reagents across four reporting segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services (which includes CRO services). Its scale, breadth of portfolio, and entrenched customer relationships across pharma, biotech, academic, government, and industrial end-markets make it a platform compounder rather than a single-product vendor, often described as a 'picks-and-shovels' play on global R&D spending. The current investor narrative centers on a reacceleration story: after a multi-year post-pandemic destocking drag, revenue growth has returned to high-single digits, management has raised guidance, and commentary around AI-driven internal efficiencies and productivity has reinforced the margin-expansion thesis. That improving fundamental backdrop, combined with the company's defensive growth profile and modest inflation risk flagged amid Middle East tensions, has driven a sharp re-rating and a vigorous debate over whether the stock has run ahead of its earnings power.…
TMO
Thermo Fisher Scientific Inc.
$691.33
Related headlines
Investment Opinion: Should I buy TMO Today?
Rating: Hold (with a constructive bias toward accumulating on pullbacks). The core thesis is that Thermo Fisher is a high-quality, cash-generative life-sciences compounder whose revenue reacceleration (+9.13% YoY in Q3 2026 to $12.137B) and sequential gross-margin expansion (40.67% → 41.21% → 42.78% across Q1-Q3 2026) are real and durable, but the stock at $700.22 already discounts much of that recovery, leaving only ~8.0% upside to the $756.52 average analyst target despite a 'strong_buy' consensus (23 Buy / 3 Hold / 1 Sell, recommendation mean 1.44).
Supporting evidence is genuinely strong on fundamentals: revenue has progressed steadily each quarter ($11.005B → $11.994B → $12.137B), Q3 gross margin of 42.78% exceeds the 41.21% year-ago level, and TTM free cash flow of $7.596B on a $217.9B market cap yields ~3.5% while funding $4.0B of 2026 buybacks, $1.107B of Q3 debt repayment, and an $8.87B acquisition. The catch is valuation: a 32.61x trailing PE, 25.20x forward PE, 21.58x EV/EBITDA and a PEG of 4.54 embed roughly 29% forward EPS growth to $37.24, and the stock sits at ~90.7% of its 52-week range ($435.27-$727.56) after a 59.74% six-month run that beat SPY by 57.61 points. With a beta of 0.845 the risk is not market correlation but multiple compression if delivery slips.
Three risks could invalidate the thesis: (1) forward EPS of $37.24 misses, forcing the 25.2x forward multiple to reset toward the ~15.8x implied by the $590 analyst low target; (2) biopharma R&D spending stalls, pressuring the $6.82B Laboratory Products & Biopharma Services segment that dominates the revenue mix; (3) 'modest inflation' flagged amid Middle East tensions erodes the margin-expansion story, compounded by $417M quarterly interest expense on 0.737 debt-to-equity. This Hold would upgrade to Buy on a pullback toward the $650-$660 October consolidation zone (implying ~22x forward EPS) or on a confirmed Q4 beat with 2027 guidance above the $59.2B consensus; it would downgrade to Sell if gross margin rolls back below 41% or forward EPS guidance is cut. Verdict: fairly valued to modestly rich relative to its own history and the premium-defensive cohort — a quality franchise worth owning, but not at a price that offers a compelling margin of safety today.
Sign up to view all
TMO 12-Month Price Forecast
The forward view is balanced: TMO's fundamental trajectory is genuinely improving, with revenue growth of 9.13% YoY, sequential gross-margin expansion to 42.78%, and $7.596B of TTM free cash flow supporting buybacks, debt paydown, and M&A. But the market has already paid for much of that recovery — the 25.20x forward PE embeds ~29% EPS growth to $37.24, and the average analyst target of $756.52 sits only ~8.0% above the current $700.22, while the wide $590-$830 target range signals real disagreement about the durability of the reacceleration. The base case (55% probability) is a grind toward $740-$770 as earnings are delivered without further multiple expansion; the bear case (25%) centers on a forward-EPS miss or margin rollback driving the stock toward $590-$650. I would upgrade to bullish on a confirmed Q4 beat with 2027 guidance above $59.2B or a pullback to the $650-$660 zone that restores a margin of safety, and downgrade to bearish if gross margin falls back below 41% or forward EPS guidance is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $756.52 and implied upside of +9.4% versus the current price.
Average Target
$756.52
27 analysts
Implied Upside
+9.4%
vs. current price
Analyst Count
27
covering this stock
Price Range
$590 - $830
Analyst target range
Coverage is deep and overwhelmingly bullish: 25 analysts rate the stock, with 23 Buy, 3 Hold, and 1 Sell, producing a consensus recommendation of 'strong_buy' and a recommendation mean of 1.44 (where 1.0 is a strong buy). The average target price of $756.52 implies roughly +8.0% upside from the current $700.22, a modest but positive expected return that suggests the sell-side sees the stock as fairly-to-attractively valued after its run rather than deeply undervalued. The consensus leans clearly bullish, and the recent institutional ratings flow — Argus, Citigroup, Barclays, Stifel, Baird, TD Cowen, and Morgan Stanley all reiterating Buy/Overweight/Outperform in October 2026 — confirms that conviction has not wavered despite the 60% six-month rally.\n\nThe target range of $590 to $830 is wide, spanning a -15.7% downside to a +18.5% upside from the current price, which signals meaningful dispersion in assumptions about the durability of the growth reacceleration. The high target of $830 likely assumes multiple expansion on top of the $37.24 forward EPS — perhaps a return to the 22x-23x forward PE seen in stronger periods — plus upside from AI-driven margin gains and accretive M&A. The low target of $590 implies roughly 15.8x forward EPS, pricing in margin compression, a slower biopharma spending recovery, or multiple de-rating as the market rotates away from premium defensives. The wide spread, combined with the fact that the average target sits only ~8% above the current price, suggests the stock is near fair value on consensus numbers and that further upside depends on earnings beats rather than multiple re-rating.
Bulls vs Bears: TMO Investment Factors
The bull case currently has the stronger evidence: revenue is genuinely reaccelerating (+9.13% YoY), gross margins are expanding sequentially (40.67% → 42.78%), free cash flow is robust ($7.596B TTM), and 23 of 25 analysts rate the stock a Buy with a $756.52 average target. The bear case rests less on fundamentals than on price — a 32.61x trailing PE, a PEG of 4.54, and a stock sitting 3.8% below its 52-week high after a 59.74% six-month run mean the good news is largely in the price. The single most important tension is whether the forward EPS of $37.24 (implying ~29% earnings growth) is actually delivered: if margins keep expanding on AI-driven efficiencies and biopharma spending recovers, the 25.2x forward multiple is digestible; if growth stalls, the multiple has room to compress toward the high-teens EV/EBITDA seen in weaker periods. Net, this is a high-quality compounder in a strong uptrend, but one where the risk/reward at $700 is balanced rather than compelling.
Bullish
- Revenue reacceleration now confirmed: Q3 2026 revenue of $12.137B grew 9.13% YoY versus $11.122B in Q3 2025, and the sequential path ($11.005B Q1 → $11.994B Q2 → $12.137B Q3) shows steady progression rather than a one-quarter bounce. Consensus forward revenue of ~$59.2B implies high-single-digit growth continues, supporting the view that the post-COVID destocking drag is fully behind the company.
- Gross margin expanding quarter over quarter: Gross margin climbed from 40.67% in Q1 to 41.21% in Q2 to 42.78% in Q3 2026, above the 41.21% year-ago Q3 2025 level. The AI-driven productivity and efficiency narrative is showing up in the actual margin line, which is the key lever behind the forward EPS step-up to $37.24.
- Overwhelming analyst conviction: 23 of 25 analysts rate TMO a Buy, with a recommendation mean of 1.44 (strong buy) and an average target of $756.52, implying ~8.0% upside from $700.22. Seven separate institutions (Argus, Citi, Barclays, Stifel, Baird, TD Cowen, Morgan Stanley) reiterated Buy/Overweight/Outperform in October 2026 despite the 60% six-month rally, showing conviction has not wavered.
- Cash generation funds buybacks and M&A: TTM free cash flow of $7.596B on a $217.9B market cap is a ~3.5% FCF yield, and Q3 alone produced $2.113B of FCF on just $437M of capex. Management deployed $3.0B of buybacks in Q1 and $1.0B in Q2 plus $1.107B of debt repayment in Q3, while still funding an $8.87B acquisition — a capital-light model with ample internal funding.
Bearish
- Valuation leaves little room for error: At a 32.61x trailing PE, 25.20x forward PE, 21.58x EV/EBITDA and a PEG of 4.54, TMO trades at a premium that already prices in the earnings recovery. The average analyst target of $756.52 sits only ~8% above the current price, meaning further upside must come from earnings beats rather than multiple re-rating.
- Stock near top of 52-week range: At $700.22, TMO sits at roughly 90.7% of its 52-week range ($435.27 low to $727.56 high), just 3.8% below the high, after a 59.74% six-month run. That positioning offers minimal margin for error and makes the stock vulnerable to profit-taking on any disappointment.
- Momentum is decelerating: The 1-month change of +4.01% and 3-month change of +19.03% are strong but well below the +59.74% six-month gain, indicating the sharpest leg of the move already happened. A stock that has front-loaded its returns can stall or consolidate for extended periods even when fundamentals remain intact.
- Wide target dispersion signals uncertainty: The analyst target range of $590 to $830 spans -15.7% downside to +18.5% upside from the current price, a very wide band. The $590 low target implies only ~15.8x forward EPS, pricing in margin compression or a slower biopharma spending recovery — a reminder that the reacceleration thesis is not universally accepted.
TMO Technical Analysis
TMO is in a powerful, sustained uptrend, with the stock up 20.70% over the trailing year and an extraordinary 59.74% over six months, closing at $700.22 on 2026-11-13. That price sits at roughly 90.7% of the 52-week range (low $435.27, high $727.56), just 3.8% below the high — a positioning that signals strong momentum but also leaves little margin for error, since the stock is trading near the top of its annual band rather than in a value pocket. The 52-week low of $435.27 implies the stock has nearly recovered its full drawdown from a max drawdown of -31.45%, underscoring how complete the turnaround in price has been.\n\nShort-term momentum is positive but decelerating relative to the medium-term surge: the 1-month change is +4.01% and the 3-month change is +19.03%, both strong but well below the +59.74% six-month gain, indicating the sharpest leg of the move occurred earlier in the year. Critically, TMO is dramatically outperforming the market — relative strength is +6.27 points over 1 month, +21.86 over 3 months, and +57.61 over 6 months versus SPY's -2.26%, -2.83%, and +2.13% respective moves — a divergence that reflects genuine idiosyncratic demand for the shares rather than beta-driven rallying. The stock's beta of 0.845 confirms it is less volatile than the market, so this outperformance is being achieved with below-market risk, which is a high-quality signal.\n\nKey technical levels are the $727.56 52-week high as immediate resistance and the $435.27 52-week low as the deep support floor, with the $650-$660 zone (the October consolidation area) acting as nearer-term support. A breakout above $727.56 would confirm the uptrend's continuation and likely trigger momentum-chasing flows, while a breakdown below $650 would signal the first meaningful crack in the trend and put the $600 area in play. With a beta of 0.845 and a max drawdown of -31.45% over the period, position sizing should account for a stock that is defensive relative to the market but still capable of sharp, sentiment-driven pullbacks after a 60% six-month run.
Beta
0.84
0.84x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$728
Price range past year
Annual Return
+19.5%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | -3.0% |
| 3m | +17.4% | -3.6% |
| 6m | +53.0% | -0.2% |
| 1y | +19.5% | +10.1% |
| ytd | +16.7% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue is reaccelerating convincingly: Q3 2026 revenue of $12.137 billion grew 9.13% year-over-year versus $11.122 billion in Q3 2025, and the sequential trajectory ($11.005B in Q1, $11.994B in Q2, $12.137B in Q3) shows steady upward progression. The Laboratory Products and Biopharma Services segment is the largest contributor at $6.82 billion, followed by Life Sciences Solutions at $2.279 billion, Analytical Instruments at $1.948 billion, and Specialty Diagnostics at $1.09 billion — a diversified mix where the biopharma services and life sciences franchises are driving the recovery. Consensus estimates of roughly $59.2 billion in forward revenue imply continued high-single-digit growth, supporting the thesis that the post-COVID destocking headwind is fully behind the company.\n\nProfitability is solid and improving: Q3 2026 net income was $1.721 billion on a 14.18% net margin, with gross margin of 42.78% and operating margin of 18.65%, both above the year-ago Q3 2025 levels of 41.21% gross and 18.66% operating. The gross margin trend across 2026 ($40.67% in Q1, 41.21% in Q2, 42.78% in Q3) is clearly expanding, and the trailing gross margin of 40.93% and net margin of 15.12% reflect the drag from earlier, weaker quarters. EPS has climbed from $4.43 diluted in Q1 to $4.68 in Q2 and $4.65 in Q3, and the forward EPS estimate of $37.24 versus the trailing figure implies the market expects continued double-digit earnings growth — consistent with the company's margin-expansion and AI-efficiency narrative.\n\nThe balance sheet is healthy but actively managed: debt-to-equity stands at 0.737, the current ratio is 1.89, and TTM free cash flow is $7.596 billion against a $217.9 billion market cap, a roughly 3.5% FCF yield. Q3 2026 alone generated $2.55 billion of operating cash flow and $2.113 billion of free cash flow on just $437 million of capex, demonstrating the capital-light, cash-generative nature of the model. ROE of 12.61% and ROA of 5.19% are respectable for a capital-intensive instruments business, and the company returned capital aggressively in 2026 — $3.0 billion of buybacks in Q1 and $1.0 billion in Q2, plus $1.107 billion of debt repayment in Q3 — funded partly by a $8.87 billion acquisition in Q1, showing management is willing to lever up for strategic M&A while still generating ample internal cash.
Quarterly Revenue
$12.1B
2026-09
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
42.8%
Latest Quarter
Free Cash Flow
$7.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Because TMO is solidly profitable (Q3 2026 net income of $1.721 billion), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 32.61x versus a forward PE of 25.20x — a meaningful 23% compression that implies the market expects earnings to grow roughly 29% over the next twelve months, consistent with the $37.24 consensus forward EPS versus the trailing run-rate. That gap is the crux of the valuation debate: the market is paying today for tomorrow's margin-driven earnings recovery.\n\nRelative to its own history, TMO's current multiples sit in the middle-to-upper portion of its multi-year band: the trailing PE of 32.61x compares with historical quarterly readings ranging from roughly 23.8x (Q2 2025) to 43.1x (Q1 2023), and the current PS ratio of 4.89x is well below the 14x-22x PS readings seen in 2022-2024 on a per-share basis but above the 15.8x-17.8x levels of mid-2025. The PEG ratio of 4.54 and EV/EBITDA of 21.58x indicate the stock is not cheap on absolute measures, and the price-to-free-cash-flow ratio of roughly 27.9x (pcf_ratio) reflects a premium for quality and cash generation. The premium is defensible given the company's market-leading position, expanding margins, and 9%+ revenue growth, but it leaves limited room for disappointment.\n\nPeer comparison is constrained by the absence of explicit industry-average multiples in the provided valuation data, so a precise premium/discount spread cannot be quantified; qualitatively, TMO's 32.6x trailing PE and 21.6x EV/EBITDA are consistent with a premium life-sciences-tools franchise trading above the broader healthcare sector, justified by its scale, recurring consumables mix, and superior free cash flow conversion. Investors should watch whether the forward multiple of 25.2x holds as earnings are delivered — if growth meets consensus, the stock can digest its premium; if growth stalls, the multiple has room to compress toward the high-teens EV/EBITDA levels seen in weaker periods.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
35.2x
Industry PE ~35.2x*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the premium valuation's dependence on continued earnings delivery. The forward PE of 25.20x versus trailing 32.61x embeds roughly 29% earnings growth, so any shortfall in the $37.24 consensus forward EPS would force a multiple reset. Debt-to-equity of 0.737 and $417M of quarterly interest expense reflect an $8.87B acquisition in Q1 funded partly with leverage, and management has flagged 'modest inflation' risk amid Middle East tensions that could pressure the 42.78% gross margin. Revenue is also concentrated in Laboratory Products & Biopharma Services at $6.82B of the $12.137B quarterly total, tying a majority of sales to biopharma R&D spending cycles.
Market and competitive risks are dominated by valuation compression. At 32.61x trailing PE, 21.58x EV/EBITDA and a PEG of 4.54, TMO trades at a premium to the broader healthcare sector, and the average analyst target of $756.52 implies only ~8.0% upside — the market is already paying for the recovery. With a beta of 0.845 the stock is defensively positioned, but that did not prevent a -31.45% max drawdown in the period, and a rotation away from premium defensives would hit the multiple hardest. The wide $590-$830 analyst target range and the $590 low target (implying ~15.8x forward EPS) show that some investors already model margin compression or a slower biopharma spending recovery.
Worst-case scenario: biopharma R&D budgets stall, the AI-efficiency margin gains fail to materialize, and the forward multiple compresses toward the high-teens EV/EBITDA seen in weaker periods. From $700.22, a re-rating to the $590 analyst low target would mean roughly -15.7%, and a fuller de-rating toward the $435.27 52-week low would mean approximately -37.8%. The stock's -31.45% max drawdown over the period is a realistic guide to how far sentiment can swing after a 59.74% six-month run, so investors should size positions for a potential 30%+ drawdown even in a fundamentally sound franchise.
FAQ
Ranked by severity: first, valuation compression — at 25.20x forward PE and a PEG of 4.54, the stock embeds ~29% EPS growth, and a miss on the $37.24 forward EPS could drive a re-rating toward the ~15.8x implied by the $590 low target (-15.7%). Second, end-market concentration — Laboratory Products & Biopharma Services accounts for $6.82B of the $12.137B quarterly revenue, so a stall in biopharma R&D budgets would hit the majority of the business. Third, margin and cost pressure — management has flagged 'modest inflation' amid Middle East tensions, and $417M of quarterly interest expense on 0.737 debt-to-equity (following an $8.87B acquisition) could squeeze the 42.78% gross margin. Fourth, momentum and positioning risk — the stock sits at ~90.7% of its 52-week range after a 59.74% six-month run, and its -31.45% max drawdown shows how sharply sentiment can reverse even in a low-beta (0.845) defensive name.
The 12-month forecast is scenario-weighted toward a modest grind higher. The base case (55% probability) targets $740-$770, assuming forward EPS of $37.24 and revenue near $59.2B are delivered and the 25.2x forward multiple holds, yielding roughly 8% upside to the $756.52 average target. The bull case (20%) targets $790-$830 on a Q4 beat with 2027 guidance above $59.2B, gross margin above 43%, and a re-rating toward 22x-23x forward earnings, approaching the $830 analyst high. The bear case (25%) targets $590-$650 if forward EPS misses or margins roll back below 41%, compressing the multiple toward the $590 low target. The base case is most likely, and its key assumption is that earnings are delivered without further multiple expansion after the 59.74% six-month run.
TMO screens as fairly valued to modestly rich. The trailing PE of 32.61x compresses to 25.20x on forward EPS of $37.24, implying the market expects roughly 29% earnings growth, while EV/EBITDA of 21.58x, price-to-free-cash-flow of ~27.9x, and a PEG of 4.54 all point to a premium multiple. Relative to its own history, the trailing PE sits in the middle-to-upper portion of a band that has ranged from roughly 23.8x (Q2 2025) to 43.1x (Q1 2023), so it is neither at a historical extreme nor at a discount. The market is paying today for tomorrow's margin-driven recovery — the average target of $756.52 implies only ~8.0% upside, meaning further gains require earnings beats rather than multiple expansion. Verdict: a premium justified by quality and cash generation, but not a valuation that offers a margin of safety.
From a risk/reward perspective, TMO is a good business at a fair-to-full price rather than a compelling bargain. The bull case is well supported: revenue grew 9.13% YoY to $12.137B in Q3 2026, gross margin expanded to 42.78%, TTM free cash flow is $7.596B, and 23 of 25 analysts rate it Buy with a $756.52 average target — about 8.0% upside from $700.22. The biggest downside risk is multiple compression: at 25.20x forward PE and a PEG of 4.54, a forward-EPS miss could send shares toward the $590 analyst low target, roughly -15.7%. It is a reasonable buy for long-term investors with a multi-year horizon who can tolerate a 15-30% drawdown, and a better buy on a pullback toward the $650-$660 zone that restores a margin of safety; momentum-chasing at 3.8% below the 52-week high after a 59.74% six-month run offers a thinner risk/reward.
TMO is structurally suited to long-term holding rather than short-term trading. It is a mature, market-leading franchise with 125,000 employees, a diversified four-segment revenue mix, $7.596B of TTM free cash flow, and a beta of 0.845 that makes it less volatile than the market — characteristics that reward patience rather than tactical positioning. The dividend yield of just 0.29% with a 9.4% payout ratio means income is not the draw; total return depends on earnings compounding and modest multiple stability. Short-term traders face a stock at ~90.7% of its 52-week range after a 59.74% six-month run, with decelerating 1-month (+4.01%) and 3-month (+19.03%) momentum and a -31.45% max drawdown history that argues against chasing. A suggested minimum holding period is three to five years, ideally entered on pullbacks toward the $650-$660 support zone to improve the entry multiple.

